Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential

被引:69
作者
Kasahara, T
Tomita, K
Murano, H
Harada, T
Tsubakimoto, K
Ogihara, T
Ohnishi, S
Kakinuma, C
机构
[1] Mochida Pharmaceut Co Ltd, Pharma Res Ctr, Shizuoka 4128524, Japan
[2] Mochida Pharmaceut Co Ltd, Res Planning & Management, Shizuoka 4128524, Japan
[3] Mochida Pharmaceut Co Ltd, Dev Res, Shizuoka 4128524, Japan
关键词
phospholipidosis; cationic amphiphilic drug; NBD-PC; Hoechst33342; HTS-PL assay;
D O I
10.1093/toxsci/kfj067
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Excessive accumulation of phospholipids results in phospholipidosis (PL), which may interfere with cellular functions, leading to acute or chronic disease or even death. Electron-microscopic detection of cytoplasmic lamellar bodies is often used as a diagnostic criterion of PL, but a faster, more convenient procedure is required for high-throughput assay of the PL-inducing potential of candidate drugs. We have developed a 96-well microplate cell-culture method for detecting PL, using a phosphatidylcholine-conjugated dye (NBD-PC) and a fluoro-microplate reader. The fluorescence intensity due to NBD-PC was normalized to that of Hoechst33342, used as an indicator of cell number, to obtain the amount of NBD-PC taken up per living cell. To select a suitable cell type, we examined the PL-detection sensitivity of five cell lines, as well as human and rat primary hepatocyte cultures, with five cationic amphiphilic drugs (CAD) as PL inducers and a negative control compound. The cell lines CHO-K1 and CHL/IU gave the best results. The NBD-PC uptake per CHO-K1 cell showed a high correlation with the pathological score of PL for 24 compounds, including PL-positive and negative compounds. This high-throughput screening assay for PL-inducing potential (HTS-PL assay) offers high sensitivity and accuracy, and it allows simultaneous determination of cytotoxicity.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 15 条
[1]   Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes [J].
Gum, RJ ;
Hickman, D ;
Fagerland, JA ;
Heindel, MA ;
Gagne, GD ;
Schmidt, JM ;
Michaelides, MR ;
Davidsen, SK ;
Ulrich, RG .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (12) :1661-1673
[2]  
JOSHI UM, 1988, J PHARMACOL EXP THER, V246, P150
[4]  
KODAVANTI UP, 1990, PHARMACOL REV, V42, P327
[5]   VESICLES OF VARIABLE DIAMETER PREPARED BY A MODIFIED INJECTION METHOD [J].
KREMER, JMH ;
ESKER, MWJ ;
PATHMAMANOHARAN, C ;
WIERSEMA, PH .
BIOCHEMISTRY, 1977, 16 (17) :3932-3935
[6]   CHLORPHENTERMINE-INDUCED LIPIDOSIS-LIKE ULTRASTRUCTURAL ALTERATIONS IN LUNGS AND ADRENAL-GLANDS OF SEVERAL SPECIES [J].
LULLMANN.R ;
REIL, GH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1974, 30 (03) :408-421
[7]   Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats [J].
Reasor, MJ ;
McCloud, CM ;
Beard, TL ;
Ebert, DC ;
Kacew, S ;
Gardner, MF ;
Aldern, KA ;
Hostetler, KY .
TOXICOLOGY, 1996, 106 (1-3) :139-147
[8]  
ROGER GU, 1991, TOXICOL METHOD, V1, P89
[9]   A toxicogenomic approach to drug-induced phospholipidosis:: Analysis of its induction mechanism and establishment of a novel in vitro screening system [J].
Sawada, H ;
Takami, K ;
Asahi, S .
TOXICOLOGICAL SCIENCES, 2005, 83 (02) :282-292
[10]   DRUG-INDUCED PHOSPHOLIPIDOSIS .2. ALTERATIONS IN PHOSPHOLIPID PATTERN OF ORGANS FROM MICE, RATS AND GUINEA-PIGS AFTER CHRONIC TREATMENT WITH CHLORPHENTERMINE [J].
SEILER, KU ;
WASSERMANN, O .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1975, 288 (2-3) :261-268